| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6242490 | Respiratory Medicine | 2013 | 8 Pages |
Abstract
Omalizumab therapy initiation was associated with decreased doses of ICS, SABA, and LTM over 2 years of follow-up for the majority of patients in a “real-world” cohort study of moderate-to-severe allergic asthma patients.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Hubert Chen, Mark D. Eisner, Tmirah Haselkorn, Benjamin Trzaskoma,